In our (inaudible), which will examine a 40 milligram glatiramer acetate injection dosed three times weekly, initiated patient recruitment during the second quarter of 2010.
Physicians and patients will have to carefully weigh the risk against the benefits for emerging all therapies, which are associated with serious safety concerns.